

S 501

Fair Prescription Drug Competition Act

Congress: 111 (2009–2011, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Feb 26, 2009

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Feb 26, 2009)

Official Text: <https://www.congress.gov/bill/111th-congress/senate-bill/501>

Sponsor

Name: Sen. Rockefeller, John D., IV [D-WV]

Party: Democratic • **State:** WV • **Chamber:** Senate

Cosponsors (7 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Brown, Sherrod [D-OH]	D · OH		Feb 26, 2009
Sen. Inouye, Daniel K. [D-HI]	D · HI		Feb 26, 2009
Sen. Kohl, Herb [D-WI]	D · WI		Feb 26, 2009
Sen. Leahy, Patrick J. [D-VT]	D · VT		Feb 26, 2009
Sen. Schumer, Charles E. [D-NY]	D · NY		Feb 26, 2009
Sen. Shaheen, Jeanne [D-NH]	D · NH		Feb 27, 2009
Sen. Stabenow, Debbie [D-MI]	D · MI		Mar 3, 2009

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Feb 26, 2009

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Feb 26, 2009)

Fair Prescription Drug Competition Act - Amends the Federal Food, Drug, and Cosmetic Act to prohibit a holder of a new, approved drug application from commencing to manufacture, market, sell, or distribute a generic version of such drug from the time of the receipt of notice from the generic manufacturer that an abbreviated new drug application has been submitted for approval until the expiration or forfeiture of the exclusivity period granted to the generic manufacturer.

Actions Timeline

- **Feb 26, 2009:** Introduced in Senate
- **Feb 26, 2009:** Sponsor introductory remarks on measure. (CR S2569-2570)
- **Feb 26, 2009:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.